Alumis Inc ALMS

$6.78 -0.04 (-0.59%)

Valuation

Market cap
882,747,000
Revenue TTM
$24,050,000
Net income TTM
$-243,330,000
PE ratio
0.00
Forward PE
—
Profit margin
-1,011.77%
Debt to equity
0.00

Trading

Volume
1,230,100
Avg volume
3,019,524
Day's range
$6.48 – $6.82
Shares out
129,435,000
Stochastic %K
77%
Beta
-0.38
Analysts
Strong Sell
Price target
$31.12

Price

Company profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory a...

Show more

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 231 6625
Website
https://www.alumis.com
Address
280 East Grand Avenue, South San Francisco, United States

Latest news

Stocktwits

chartistmind Oct 21, 6:11 PM
$ALMS #7295 10% + 🚀 ripper within just days on the highest conviction lot.
0 replies
Dameistro Oct 21, 2:25 PM
$ALMS breakout above resistance
0 replies
Kn1fecatche12 Oct 21, 2:02 PM
$ALMS constant accumulation over the last few days off the lows, shorts can sit and watch their gains evaporate. There’s a reason the big boys sold over 20k+ Jan 2027 $7 puts (2M +share equivalent). They made a ton collecting that premium and don’t mind getting exercised bc they’re accumulating everything they can at these levels. All the data about Envu is pointing to a big home run for ALMS. They just need to monetize all that potential ASAP.
0 replies
chartistmind Oct 20, 7:17 PM
$ALMS
1 replies
Uiua Oct 18, 11:36 AM
$ALMS my average price is 7.79 dollars, I am fully all in, probably I am taking a huge risk but I believe I can easy double my money
0 replies
pennyundertaker Oct 17, 8:01 AM
$ALMS just found out Samsara has ALMS in their portfolio! Cam it do a AbVX move?
0 replies
joemist1 Oct 16, 1:15 PM
$ALMS I reloaded here
0 replies
ipeefreely Oct 16, 2:15 AM
$ALMS they need to file that fda application asap and seek a partner for commercialization. They’ve got a good product going via their psoriasis drug.. let’s hope management doesn’t botch this opportunity.
0 replies